Everolimus for the treatment of epithelioid hemangioma: a case report

1Citations
Citations of this article
9Readers
Mendeley users who have this article in their library.

Abstract

Epithelioid hemangioma is a rare benign vascular tumor manifested as slow-growing subcutaneous or dermal nodules. A previously therapeutic strategy involved surgical excision and sclerotherapy. However, no standard treatment has been established. Here, we reported an atypical case of epithelioid hemangioma that had a locally aggressive behavior and was successfully treated with everolimus, a rapamycin analog used for cancer therapy. A 1-year-old boy presented with an ulcerated lump in the left palmar region. The imaging test results, confirmed through histopathologic examination, suggested a diagnosis of epithelioid hemangioma. Targeted therapy with everolimus was administered orally because of a minimal response to initial transarterial sclerotherapy. The patient achieved a satisfactory response with a significantly reduced lesion size and improved hand function after a 2-year follow-up. This finding showed that patients with locally aggressive forms of epithelioid hemangioma may significantly benefit from everolimus as a potential targeted therapy.

Cite

CITATION STYLE

APA

Aisyi, M., Syarif, A. H., Mukarramah, D. A., Hermawan, R., & Iriani, D. (2021). Everolimus for the treatment of epithelioid hemangioma: a case report. Medical Journal of Indonesia, 30(4), 301–305. https://doi.org/10.13181/mji.cr.205036

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free